Loading
A phase 3 trial of Rilvegostomig, Capecitabine and Gemcitabine + cisplatin in biliary tract cancer, run by AstraZeneca, active and no longer recruiting.
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) is a phase 3 interventional study registered as NCT06109779 by AstraZeneca, with 760 participants enrolled, started 2023-12-04 and due to reach its primary completion in 2029-01-02. Interventions recorded: Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin and S-1 [Tegafur/Oteracil/gimeracil].
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rilvegostomig, Gemcitabine + cisplatin, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Rilvegostomig, Capecitabine, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares Gemcitabine + cisplatin, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Rilvegostomig, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, Capecitabine, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, Capecitabine, AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/